Patents by Inventor Daniel L. Rosewater

Daniel L. Rosewater has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of chemically assembled electronic nanotechnology circuit fabrication
    Patent number: 7064000
    Abstract: Chemically assembled electronic nanotechnology (CAEN) provides an alternative to using Complementary Metal Oxide Semiconductor (CMOS) for constructing circuits with feature sizes in the tens of nanometers. A molecular latch and a method using the latch that enables it to act as a state holding device, perform voltage restoration, and to provide I/O isolation is disclosed.
    Type: Grant
    Filed: July 12, 2004
    Date of Patent: June 20, 2006
    Assignee: Carnegie Mellon University
    Inventors: Seth Copen Goldstein, Daniel L. Rosewater
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
    Patent number: 6972293
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: June 30, 2003
    Date of Patent: December 6, 2005
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Electronic circuit device, system, and method
    Publication number: 20040257736
    Abstract: Chemically assembled electronic nanotechnology (CAEN) provides an alternative to using Complementary Metal Oxide Semiconductor (CMOS) for constructing circuits with feature sizes in the tens of nanometers. A molecular latch and a method using the latch that enables it to act as a state holding device, perform voltage restoration, and to provide I/O isolation is disclosed.
    Type: Application
    Filed: July 12, 2004
    Publication date: December 23, 2004
    Inventors: Seth Copen Goldstein, Daniel L. Rosewater
  • Molecular scale latch and associated clocking scheme to provide gain, memory and I/O isolation
    Patent number: 6777982
    Abstract: Chemically assembled electronic nanotechnology (CAEN) provides an alternative to using Complementary Metal Oxide Semiconductor (CMOS) for constructing circuits with feature sizes in the tens of nanometers. A molecular latch and a method using the latch that enables it to act as a state holding device, perform voltage restoration, and to provide I/O isolation is disclosed.
    Type: Grant
    Filed: April 3, 2002
    Date of Patent: August 17, 2004
    Assignee: Carnegie Mellon University
    Inventors: Seth Copen Goldstein, Daniel L. Rosewater
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
    Publication number: 20040023993
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: June 30, 2003
    Publication date: February 5, 2004
    Applicant: Neurogen Corporation A Corporation of the State of Delaware
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
    Patent number: 6627624
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: September 30, 2003
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors
    Publication number: 20030092912
    Abstract: Disclosed are compounds of the formula: 1
    Type: Application
    Filed: April 3, 2002
    Publication date: May 15, 2003
    Applicant: Neurogen Corporation, a corporation of the state of Delaware
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Electronic circuit device, system, and method
    Publication number: 20020175390
    Abstract: Chemically assembled electronic nanotechnology (CAEN) provides an alternative to using Complementary Metal Oxide Semiconductor (CMOS) for constructing circuits with feature sizes in the tens of nanometers. A molecular latch and a method using the latch that enables it to act as a state holding device, perform voltage restoration, and to provide I/O isolation is disclosed.
    Type: Application
    Filed: April 3, 2002
    Publication date: November 28, 2002
    Inventors: Seth Copen Goldstein, Daniel L. Rosewater
  • Substituted cycloalkyl-4-oxonicotinic carboxamides; GABA brain receptor ligands
    Patent number: 6448259
    Abstract: Disclosed are compounds of the Formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: the C ring is a(n) (un)substituted carbocycle; X is hydrogen, hydroxyl or lower alkyl; and W is (un)substituted alkyl, aryl, arylalkyl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.
    Type: Grant
    Filed: May 5, 2000
    Date of Patent: September 10, 2002
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Daniel L. Rosewater
  • Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
    Patent number: 6380210
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 30, 2002
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Alan Hutchison, Kenneth Shaw, Daniel L. Rosewater
  • Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
    Patent number: 6194427
    Abstract: Disclosed are compounds of the Formula: or the pharmaceutically acceptable non-toxic salts thereof wherein: the C ring is a(n) (un)substituted carbocycle; X is hydrogen, hydroxyl or lower alkyl; and W is (un)substituted alkyl, aryl, arylalkyl, or heteroaryl, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors. These compounds are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.
    Type: Grant
    Filed: February 26, 1999
    Date of Patent: February 27, 2001
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, Daniel L. Rosewater